The therapeutic antibodies market to 2008

European Journal of Pharmaceutics and Biopharmaceutics

Volumn 59, Issue 3, 2005, Pages 389-396

  Pavlou, Alex K ^a   Belsey, Mark J ^a  

^a Datamonitor   (United Kingdom)

Author keywords

Chimeric; Fabs; Fully human; Humanized; Market analysis; Monoclonal antibody; Murine

Indexed keywords

ABCIXIMAB; ADALIMUMAB; ALEMTUZUMAB; BASILIXIMAB; BEVACIZUMAB; CETUXIMAB; DACLIZUMAB; EDRECOLOMAB; EFALIZUMAB; GEMTUZUMAB OZOGAMICIN; IBRITUMOMAB TIUXETAN; INFLIXIMAB; OKT 3; OMALIZUMAB; PALIVIZUMAB; RECOMBINANT ANTIBODY; RITUXIMAB; TOSITUMOMAB I 131; TRASTUZUMAB;

ARTHRITIS; CHIMERA; DRUG MARKETING; ECONOMIC ASPECT; ONCOLOGY; REVIEW;

EID: 14844285410     PISSN: 09396411     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejpb.2004.11.007     Document Type: Article

References (17)

1. G. Kohler, and C. Milstein Continuous cultures of fused cells secreting antibody of predefined specificity Nature 256 1975 495 497
2. S.L. Morrison, M.J. Johnson, L.A. Herzenberg, and V.T. Oi Chimeric human antibody molecules: mouse antigen-binding domains with human constant region domains Proc. Natl Acad. Sci. 81 1984 6851 6855
3. P.T. Jones, P.H. Dear, J. Foote, M.S. Neuberger, and G. Winter Replacing the complementarity-determining regions in a human antibody with those from a mouse Nature 321 1986 522 525
4. I. Aksentijevich, and I.W. Flinn Monoclonal antibody therapy with autologous peripheral blood stem cell transplantation for non-Hodgkin's lymphoma Cancer Control 9 2002 99 105
5. Industry databases used are: Investigational Drugs database, Thomson Current Drugs, 14 Great Queen Street, London WC2B 5DF, United Kingdom; BioSpace Clinical Competitive Intelligence System, BioSpace, 300 Fifth Ave. South, Naples, FL 34102, USA; and IMS Lifecycle, IMS Health, 7 Harewood Avenue, London NW1 6JB, United Kingdom.
6. Datamonitor plc, Charles House, 108-110 Finchley Road, London NW3 5JJ, United Kingdom.
7. O.H. Brekke, and I. Sandlie Therapeutic antibodies for human diseases at the dawn of the twenty-first century Nat. Rev. Drug Discov. 2 2003 52 62
8. S.B. Hanauer Safety of infliximab in clinical trials Aliment. Pharmacol. Ther. 13 1999 16 22
9. K. Rajagopalan, G. Pavlinkova, S. Levy, P.R. Pokkuluri, M. Schiffer, B.E. Haley, and H. Kohler Novel unconventional binding site in the variable region of immunoglobulins Proc. Natl Acad. Sci. 93 1996 6019 6024
10. M.A. Holmes, T.N. Buss, and J. Foote Conformational correction mechanisms aiding antigen recognition by a humanized antibody J. Exp. Med. 187 1998 479 485
11. M. Trikha, L. Yan, and M.T. Nakada Monoclonal antibodies as therapeutics in oncology Curr. Opin. Biotechnol. 13 2002 609 614
12. T.A. Waldmann Monoclonal antibodies in diagnosis and therapy Science 252 1991 1657 1662
13. M. Harris Monoclonal antibodies as therapeutic agents for cancer Lancet Oncol. 5 2004 292 302
14. A.N. Weir, A. Nesbitt, A.P. Chapman, A.G. Popplewell, P. Antoniw, and A.D. Lawson Formatting antibody fragments to mediate specific therapeutic functions Biochem. Soc. Trans. 30 2002 512 516
15. L. Sanz, B. Blanco, and L. Alvarez-Vallina Antibodies and gene therapy: teaching old 'magic bullets' new tricks Trends Immunol. 25 2004 85 91
16. S.A. Eccles Monoclonal antibodies targeting cancer: 'magic bullets' or just the trigger? Breast Cancer Res. 3 2001 86 90
17. M. Berger, V. Shankar, and A. Vafai Therapeutic applications of monoclonal antibodies Am. J. Med. Sci. 324 2002 14 30